Hyperion DeFi (HYPD) Competitors

$4.67 +0.17 (+3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$4.42 -0.25 (-5.25%)

As of 04:32 PM Eastern

HYPD vs. LFCR, KRRO, ABOS, UNCY, and DTIL

Should you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Lifecore Biomedical (LFCR), Korro Bio (KRRO), Acumen Pharmaceuticals (ABOS), Unicycive Therapeutics (UNCY), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry.

How does Hyperion DeFi compare to Lifecore Biomedical?

Hyperion DeFi (NASDAQ:HYPD) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

: Hyperion DeFi has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
: Lifecore Biomedical has higher revenue and earnings than Hyperion DeFi. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hyperion DeFi $810K 65.19 -$45.31M -$11.80 N/A
Lifecore Biomedical $128.87M 1.49 -$36.73M -$0.98 N/A
: In the previous week, Lifecore Biomedical had 2 more articles in the media than Hyperion DeFi. MarketBeat recorded 5 mentions for Lifecore Biomedical and 3 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.66 beat Lifecore Biomedical's score of 0.36 indicating that Hyperion DeFi is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperion DeFi
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lifecore Biomedical
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Hyperion DeFi has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -23.08%. Hyperion DeFi's return on equity of -129.97% beat Lifecore Biomedical's return on equity.
Company Net Margins Return on Equity Return on Assets
Hyperion DeFi N/A -129.97% -92.39%
Lifecore Biomedical -23.08% -1,211.09% -9.69%
: 25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Hyperion DeFi currently has a consensus target price of $5.88, indicating a potential upside of 26.73%. Lifecore Biomedical has a consensus target price of $6.00, indicating a potential upside of 16.85%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, research analysts clearly believe Hyperion DeFi is more favorable than Lifecore Biomedical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperion DeFi
2 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
Lifecore Biomedical
1 Sell rating(s)

2 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.20

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	65.19	-$45.31M	-$11.80	N/A
Lifecore Biomedical	$128.87M	1.49	-$36.73M	-$0.98	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-129.97%	-92.39%
Lifecore Biomedical	-23.08%	-1,211.09%	-9.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Hyperion DeFi beats Lifecore Biomedical on 9 of the 17 factors compared between the two stocks.

How does Hyperion DeFi compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

: Korro Bio has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500.
: Korro Bio presently has a consensus target price of $37.29, indicating a potential upside of 195.17%. Hyperion DeFi has a consensus target price of $5.88, indicating a potential upside of 26.73%. Given Korro Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Korro Bio is more favorable than Hyperion DeFi.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
1 Sell rating(s)
4 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.55
Hyperion DeFi
2 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
: Hyperion DeFi has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Korro Bio $6.39M 28.50 -$117.26M -$12.47 N/A
Hyperion DeFi $810K 65.19 -$45.31M -$11.80 N/A
: In the previous week, Hyperion DeFi had 1 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for Hyperion DeFi and 2 mentions for Korro Bio. Hyperion DeFi's average media sentiment score of 0.66 beat Korro Bio's score of 0.50 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Korro Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hyperion DeFi
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Hyperion DeFi has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Korro Bio's return on equity of -115.95% beat Hyperion DeFi's return on equity.
Company Net Margins Return on Equity Return on Assets
Korro Bio -1,834.48% -115.95% -71.32%
Hyperion DeFi N/A -129.97% -92.39%
: 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	28.50	-$117.26M	-$12.47	N/A
Hyperion DeFi	$810K	65.19	-$45.31M	-$11.80	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-115.95%	-71.32%
Hyperion DeFi	N/A	-129.97%	-92.39%

Summary

Hyperion DeFi beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Acumen Pharmaceuticals?

Hyperion DeFi (NASDAQ:HYPD) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

: 25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Hyperion DeFi presently has a consensus price target of $5.88, indicating a potential upside of 26.73%. Acumen Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 164.03%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Hyperion DeFi.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperion DeFi
2 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
Acumen Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Hyperion DeFi has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hyperion DeFi $810K 65.19 -$45.31M -$11.80 N/A
Acumen Pharmaceuticals N/A N/A -$121.33M -$2.01 N/A
: In the previous week, Hyperion DeFi had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 3 mentions for Hyperion DeFi and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.94 beat Hyperion DeFi's score of 0.66 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperion DeFi
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Acumen Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: Acumen Pharmaceuticals' return on equity of -111.26% beat Hyperion DeFi's return on equity.
Company Net Margins Return on Equity Return on Assets
Hyperion DeFi N/A -129.97% -92.39%
Acumen Pharmaceuticals N/A -111.26% -75.67%
: Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	65.19	-$45.31M	-$11.80	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-129.97%	-92.39%
Acumen Pharmaceuticals	N/A	-111.26%	-75.67%

Summary

Acumen Pharmaceuticals beats Hyperion DeFi on 8 of the 15 factors compared between the two stocks.

How does Hyperion DeFi compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

: Unicycive Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500.
: Unicycive Therapeutics has higher earnings, but lower revenue than Hyperion DeFi. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Unicycive Therapeutics $680K 318.87 -$26.56M -$2.17 N/A
Hyperion DeFi $810K 65.19 -$45.31M -$11.80 N/A
: In the previous week, Unicycive Therapeutics had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 3 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.66 beat Unicycive Therapeutics' score of 0.55 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hyperion DeFi
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Unicycive Therapeutics currently has a consensus price target of $24.75, suggesting a potential upside of 204.77%. Hyperion DeFi has a consensus price target of $5.88, suggesting a potential upside of 26.73%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Hyperion DeFi.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
Hyperion DeFi
2 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
: Hyperion DeFi's return on equity of -129.97% beat Unicycive Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Unicycive Therapeutics N/A -144.30% -87.28%
Hyperion DeFi N/A -129.97% -92.39%
: 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	318.87	-$26.56M	-$2.17	N/A
Hyperion DeFi	$810K	65.19	-$45.31M	-$11.80	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-144.30%	-87.28%
Hyperion DeFi	N/A	-129.97%	-92.39%

Summary

Unicycive Therapeutics beats Hyperion DeFi on 9 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

: Precision BioSciences has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500.
: Precision BioSciences currently has a consensus price target of $36.33, suggesting a potential upside of 395.41%. Hyperion DeFi has a consensus price target of $5.88, suggesting a potential upside of 26.73%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Precision BioSciences is more favorable than Hyperion DeFi.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision BioSciences
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Hyperion DeFi
2 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
: Hyperion DeFi has a net margin of 0.00% compared to Precision BioSciences' net margin of -133.45%. Precision BioSciences' return on equity of -122.60% beat Hyperion DeFi's return on equity.
Company Net Margins Return on Equity Return on Assets
Precision BioSciences -133.45% -122.60% -48.98%
Hyperion DeFi N/A -129.97% -92.39%
: 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Hyperion DeFi has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Precision BioSciences $34.26M 5.52 -$45.72M -$5.13 N/A
Hyperion DeFi $810K 65.19 -$45.31M -$11.80 N/A
: In the previous week, Precision BioSciences had 3 more articles in the media than Hyperion DeFi. MarketBeat recorded 6 mentions for Precision BioSciences and 3 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.66 beat Precision BioSciences' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Precision BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Hyperion DeFi
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-133.45%	-122.60%	-48.98%
Hyperion DeFi	N/A	-129.97%	-92.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.52	-$45.72M	-$5.13	N/A
Hyperion DeFi	$810K	65.19	-$45.31M	-$11.80	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precision BioSciences beats Hyperion DeFi on 9 of the 17 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPD vs. The Competition

Export

Metric	Hyperion DeFi	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.42M	$448.53M	$6.25B	$11.87B
Dividend Yield	N/A	3.86%	2.73%	5.21%
P/E Ratio	-0.40	4.19	29.06	28.47
Price / Sales	65.19	6,881.75	475.75	61.65
Price / Cash	N/A	13.13	27.62	36.52
Price / Book	0.98	78.48	9.71	6.67
Net Income	-$45.31M	-$96.07M	$3.55B	$332.53M
7 Day Performance	8.83%	0.61%	1.65%	1.98%
1 Month Performance	42.65%	3.71%	5.54%	9.14%
1 Year Performance	306.67%	48.00%	34.16%	39.55%

Hyperion DeFi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPD Hyperion DeFi	2.9248 of 5 stars	$4.67 +3.8%	$5.88 +25.8%	N/A	$53.20M	$813.46K	N/A	40	News Coverage Gap Up
LFCR Lifecore Biomedical	1.2506 of 5 stars	$5.08 +1.2%	$5.50 +8.3%	N/A	$188.14M	$128.87M	N/A	690	Positive News
KRRO Korro Bio	3.2271 of 5 stars	$12.84 -0.4%	$37.29 +190.4%	N/A	$185.91M	$6.39M	N/A	70	Upcoming Earnings
ABOS Acumen Pharmaceuticals	2.691 of 5 stars	$2.52 -1.9%	$6.67 +164.6%	N/A	$185.59M	N/A	N/A	20	News Coverage Upcoming Earnings
UNCY Unicycive Therapeutics	3.6757 of 5 stars	$7.23 -0.8%	$25.67 +255.0%	N/A	$183.99M	N/A	N/A	9	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPD) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperion DeFi (HYPD) Competitors

HYPD vs. LFCR, KRRO, ABOS, UNCY, and DTIL

How does Hyperion DeFi compare to Lifecore Biomedical?

Summary

How does Hyperion DeFi compare to Korro Bio?

Summary

How does Hyperion DeFi compare to Acumen Pharmaceuticals?

Summary

How does Hyperion DeFi compare to Unicycive Therapeutics?

Summary

How does Hyperion DeFi compare to Precision BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperion DeFi (HYPD) Competitors

HYPD vs. LFCR, KRRO, ABOS, UNCY, and DTIL

How does Hyperion DeFi compare to Lifecore Biomedical?

Summary

How does Hyperion DeFi compare to Korro Bio?

Summary

How does Hyperion DeFi compare to Acumen Pharmaceuticals?

Summary

How does Hyperion DeFi compare to Unicycive Therapeutics?

Summary

How does Hyperion DeFi compare to Precision BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools